Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shares shot up 5.6% on Friday . The company traded as high as $3.25 and last traded at $3.22, with a volume of 240,560 shares trading hands. The stock had previously closed at $3.05.

A number of research firms recently weighed in on AUPH. Canaccord Genuity reaffirmed a “buy” rating on shares of Aurinia Pharmaceuticals in a research report on Thursday, May 12th. Zacks Investment Research raised Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, May 24th. Leerink Swann reaffirmed an “outperform” rating and set a $7.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 6th. Finally, HC Wainwright began coverage on Aurinia Pharmaceuticals in a research report on Thursday, June 30th. They set a “buy” rating and a $7.00 price objective for the company. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Aurinia Pharmaceuticals presently has an average rating of “Buy” and an average target price of $7.15.

The company’s market capitalization is $109.80 million. The firm’s 50-day moving average price is $2.90 and its 200-day moving average price is $2.65.

Aurinia Pharmaceuticals Inc (Aurinia) is a Canada-based is a clinical stage pharmaceutical company. The Company is focused on the development of its therapeutic immunomodulating drug candidate, voclosporin, which is a calcineurin inhibitor (CNI). Voclosporin is an oral drug, administered twice daily.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.